Files

DelireLouvMedInnov2024.pdf
  • Open Access
  • Adobe PDF
  • 2.59 MB
Download

Details

Authors
Show more
Abstract
(en) [Innovations 2024 in hepatogastroenterology] The year 2024 was once again marked by promising new developments in gastroenterology, whether in endoscopy, hepatology, or oncology. In endoscopy, apposition techniques have revolutionized practice. The therapeutic armamentarium for the management of primary biliary cholangitis continues to expand. The efficacy of two new compounds, elafibranor and seladelpar, was evaluated in two studies. Resmetirom was approved by the Food and Drug Administration for the treatment of metabolic steatohepatitis following positive results from a Phase III study also published this year. The first results of the Réseau Francophone pour l’Etude de l’Hépatotoxicité des Produits de Santé (REFHEPS) were presented in plenary session at the annual congress of the Société Française d’Hépatologie (AFEF) in early October. Finally, in 2024, the European Association for the Study of the Liver (EASL) published new recommendations for the screening, diagnosis, and treatment of hepatocellular carcinoma. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Delire, B., Lanthier, N., Dahlqvist, G., Deprez, P., Moreels, T., Borbath, I., Annet, L., & Horsmans, Y. (2025). Innovations 2024 en Hépato-Gastroentérologie. Louvain médical, 144(2), 67-74. https://hdl.handle.net/2078.5/256094 (Original work published 2025)